
 
 
 
 
 
 
 
 
   
 1. An isolated antibody or antibody binding fragment which binds to an epitope of activation antigen CMRF-56. 
 
     
 2. An antibody according to claim 1 wherein said antibody is a monoclonal antibody. 
 
     
 3. A monoclonal antibody according to claim 2 wherein said monoclonal antibody is monoclonal antibody CMRF-56. 
 
     
 4. Isolated monoclonal antibody CMRF-56, which antibody specifically binds to an epitope on activated human dendritic cells but does not bind to activation antigens CMRF- 44 and CD83. Hybridoma cell line CMRF-56 (ATCC HB 12202). Monoclonal antibody CMRF-56, which antibody is secreted by hybridoma cell line CMRF-56 (ATCC HB 12202) and which antibody specifically binds to an epitope on activated human dendritic cells but does not bind to activation antigens CMRF-44 and CD83. 
 
     
 7. An isolated antibody or antibody binding fragment which is specific for the epitope on human dendritic cells to which monoclonal antibody CMRF-56 binds. 
 
     
 8. A process for purifying activated dendritic cells from a sample containing such dendritic cells said process comprising the steps of: contacting said sample with an antibody or antibody binding fragment as claimed in any one of claims 1 to 4, 6 or 7; and (ii) recovering activated dendritic cells which have bound to said antibody or antibody binding fragment. P:\OPER\TDO\46393-97 specificion.doc. -29- 
 
     
 9. A process for identifying activated dendritic cells in a sample said process comprising the steps of: contacting said sample with an antibody or antibody binding fragment as claimed in any one of claims 1 to 4, 6 or 7 to form an antibody/activated dendritic cell complex; and (ii) detecting the presence of antibody/dendritic cell complexes. A process as claimed in claim 8 or claim 9 wherein said antibody is monoclonal antibody CMRF-56. 
 
     
 12. A purification system for use in purifying and/or concentrating activated dendritic cells from a sample containing such cells which system includes an antibody or antibody binding fragment as claimed in any one of claims 1 to 4, 6 or 7. 
 
     
 13. A purification system as claimed in claim 12 wherein said antibody is monoclonal antibody CMRF-56. A purification system as claimed in claim 13 wherein monoclonal antibody CMRF- 56 is biotinylated. Activated dendritic cells which are purified and/or concentrated by a process as claimed in any one of claims 8 to 11 and/or using a purification system as claimed in any one of claims 12 to 14. 
 
     
 16. An assay kit comprising monoclonal antibody CMRF-56 for use as a diagnostic marker of activated dendritic cells. P:oper\ldo\46393-97 specificion.doc- 
 
     
 17. An immunopotentiating composition comprising an antibody or binding fragment as claimed in any one of claims 1 to 4, 6 or 7, and at least one antigen capable of generating a protective immunological response to a disease in an animal susceptible to such disease. 
 
     
 18. An immunopotentiating composition as claimed in claim 17 further comprising activated dendritic cells as claimed in claim  
 
     
 19. An immunopotentiating composition comprising activated dendritic cells as claimed in claim 15 and at least one antigen capable of generating a protective immunological response to a disease in an animal susceptible to such disease. 
 
     
 20. A method of prophylaxis and/or therapy in relation to a disease which comprises administering to a subject susceptible to said disease an immunopotentiating composition as claimed in claim 17, claim 18 or claim 19. o.* DATED this third day of January 2002. The Corporation of the Trustees of the Order of the Sisters of Mercy in Queensland by DAVIES COLLISION CAVE Patent Attorneys for the Applicant 
 
   
 
 
 
 
 
 
 
 
